Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Benchmark Upgrades NeoGenomics to Buy, Maintains $20 Price Target

Benchmark analyst Bruce Jackson upgrades NeoGenomics (NASDAQ:NEO) from Hold to Buy and maintains $20 price target.

byBenzinga Newsdesk

February 24, 2023

1 minute read

Benchmark analyst Bruce Jackson upgrades NeoGenomics (NASDAQ:NEO) from Hold to Buy and maintains $20 price target.

B of A Securities Downgrades Medical Properties Trust to Neutral

By Benzinga Newsdesk

Today, 7:57 PM

B of A Securities analyst Joshua Dennerlein downgrades Medical Properties Trust (NYSE:MPW) from Buy to Neutral.

MPW

RBC Capital Upgrades Pan American Silver to Outperform, Raises Price Target to $22

By Benzinga Newsdesk

Today, 7:57 PM

RBC Capital analyst Michael Siperco upgrades Pan American Silver (NASDAQ:PAAS) from Sector Perform to Outperform and raises the price target from $19 to $22.

PAAS

News

Elon Musk Tweets ‘10.69.2.1 Coming Out In A Few Days With Additional Polish, 10.69.3 Comes Out Shortly After AI Day’

By Benzinga Newsdesk

Today, 7:57 PM

https://twitter.com/elonmusk/status/1570439829732851713

TSLA

Imax Q3 EPS $(0.08) Beats $(0.11) Estimate, Sales $56.60M Miss $57.03M Estimate

By Bill Haddad

Today, 7:57 PM

Imax (NYSE:IMAX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 89.33 percent increase over losses of $(0.75) per share from the same

IMAX

Benchmark Upgrades NeoGenomics to Buy, Maintains $20 Price Target

Related Posts

B of A Securities Downgrades Medical Properties Trust to Neutral

RBC Capital Upgrades Pan American Silver to Outperform, Raises Price Target to $22

Elon Musk Tweets ‘10.69.2.1 Coming Out In A Few Days With Additional Polish, 10.69.3 Comes Out Shortly After AI Day’

Imax Q3 EPS $(0.08) Beats $(0.11) Estimate, Sales $56.60M Miss $57.03M Estimate